Visceral pain results from the activation of nociceptors of the thoracic, pelvic, or abdominal viscera. Visceral pain is diffuse, difficult to localize and often considered by patients to have a deep, sickening component. It may be accompanied by symptoms such as nausea, vomiting, and changes in vital signs as well as emotional manifestations. Irritable bowel syndrome (IBS), a dysfunctional condition causing recurrent attacks of abdominal pain, has been estimated to affect 25% of the population in many countries and accounts for 40-50% of all gastroenterologic consultations worldwide.ABOUT ANAVEX 1066 ANAVEX 1066, a mixed Sigma-1/Sigma-2 receptor ligand, has previously demonstrated antitumor activity as well as analgesic effects in an animal model of chemotherapy-induced polyneuropathy. Current therapies for neuropathic and visceral pain are not satisfactory and thus new drugs acting on novel molecular targets are actively being investigated. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex's lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer's disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson's Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson's disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson's disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer's hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com.
Forward-Looking StatementsStatements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company's most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. For Further Information: Anavex Life Sciences Corp.Research & Business DevelopmentToll-free: 1-844-689-3939Email: firstname.lastname@example.org Investors:Matthew HainesRiver East Investor Relations, LLC917-733-9297 email@example.com Media:Dennis Dobson, Jr.Dobson Media Group(203) 258-0159 firstname.lastname@example.org